New Clinical Trials offer future Hope for Hepatitis C infected patients
> 1/21/2006 1:05:47 PM

Antisense drug trials are under way to determine the toxicity and efficacy of this new class of drugs in the treatment of Hepatitis C. The lead company in this emerging pharma technology is AVI BioPharma and they are showing promising results with their new drug in terms of low toxicity and good pharmacokinitics data in early human drug trials.

The Hepatitis Foundation International estimates that between 8,000 and 10,000 people die annually in the U.S. from HCV-related cirrhosis or liver cancer. The current treatment for HCV, 24 to 48 weeks of therapy with pegylated interferon alpha and ribavirin, is successful in less than half of the patients infected with genotype 1 HCV, the most common form of the virus in the U.S. Furthermore, this treatment has numerous side effects, some of them severe, which make it difficult for nearly half of initially treated patients to tolerate the recommended dosages and duration of treatment.

The CDC provides a very useful fact sheet on the disease and should be viewed because many people are confused about the transmission and longterm prognosis of Hepatitis C.

The Antisense drug therapies are emerging through the human genomics field's mapping efforts of how mRNA creates proteins and the role of these proteins in disease expression. These research efforts are proving fruitful and potentially could lead to huge breakthroughs for many different viral infections.

Below is a Hepatitis C Virus Particle:


We need meditation techniques and alternative healing methods that can treat and provide change for a variety of health conditions as well as promote over all well being.
Posted by: Andrew Spark 3/21/2006 6:07:17 AM

Post Your Comments

Post a comment
Email Address:
Verification Code:
Input the 8 characters you see above:


Drug Abuse
Sexual Addiction
Eating Disorders
Alzheimer's Disease

About TOL | Contact Us | Defining Behavioral Fitness | For Healthcare Professionals | Links | Privacy Policy